<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0" xmlns:media="http://search.yahoo.com/mrss/">
  <channel>
    <title>Series A</title>
    <description>
      <![CDATA[]]>
    </description>
    <link>https://www.bioworld.com/rss</link>
    <language>en-us</language>
    <item>
      <title>Tortugas launches with $106M for neurology, neuropsychiatric drugs</title>
      <description>
        <![CDATA[Tortugas Neuroscience Inc. came out of its shell to announce the raising of $106 million between its seed and series A financing rounds. “We like the symbolism of the sea turtle – long-lived, persistent, very determined,” Tortugas CEO Jeff Jonas said of the company’s name.]]>
      </description>
      <guid>http://www.bioworld.com/articles/730482</guid>
      <pubDate>Tue, 21 Apr 2026 12:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/730482-tortugas-launches-with-106m-for-neurology-neuropsychiatric-drugs</link>
      <media:content url="https://www.bioworld.com/ext/resources/BW-source/2026/Jeff-Jonas-CEO-and-Al-Robichaud-president-head-of-RD-Tortugas-4-21.webp?t=1776806199" type="image/jpeg" medium="image" fileSize="420579">
        <media:title type="plain">Jeff Jonas, CEO and Al Robichaud, president, head of R&amp;D, Tortugas Neuroscience</media:title>
        <media:description type="plain">Tortugas Neuroscience Inc. is led by Jeff Jonas, CEO (left), 
and Al Robichaud, president and head of R&amp;amp;D.
</media:description>
      </media:content>
    </item>
    <item>
      <title>Financing at Vivatides to advance extrahepatic RNA therapeutics</title>
      <description>
        <![CDATA[Vivatides Therapeutics Inc. has closed an oversubscribed $54 million series A financing to advance its work in extrahepatic RNA delivery technologies. Proceeds from the financing will be used to further advance the company’s extrahepatic delivery platform and accelerate pipeline programs.]]>
      </description>
      <guid>http://www.bioworld.com/articles/730327</guid>
      <pubDate>Mon, 13 Apr 2026 09:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/730327-financing-at-vivatides-to-advance-extrahepatic-rna-therapeutics</link>
      <media:content url="https://www.bioworld.com/ext/resources/Stock-images/Money/Dollar-sign-between-hands.webp?t=1740610521" type="image/jpeg" medium="image" fileSize="123345">
        <media:title type="plain">Dollar sign between hands</media:title>
      </media:content>
    </item>
    <item>
      <title>Realta secures another $40M for its hypoxic ischemic encephalopathy treatment</title>
      <description>
        <![CDATA[Realta Life Sciences Inc. raised an additional $40 million in the final tranche of its series A investment, bringing the total the company has raised to more than $150 million through mission-driven investors and a family-office model.]]>
      </description>
      <guid>http://www.bioworld.com/articles/730228</guid>
      <pubDate>Fri, 10 Apr 2026 12:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/730228-realta-secures-another-40m-for-its-hypoxic-ischemic-encephalopathy-treatment</link>
      <media:content url="https://www.bioworld.com/ext/resources/Stock-images/Therapeutic-topics/Pediatric/newborn-baby-infant.webp?t=1720795419" type="image/jpeg" medium="image" fileSize="169571">
        <media:title type="plain">Photo of hands holding a baby </media:title>
      </media:content>
    </item>
    <item>
      <title>Stipple launches with $100M for novel oncology targets</title>
      <description>
        <![CDATA[Stipple Bio Inc. raised $100 million in a series A financing to support progression of the company’s lead drug, STP-100, an antibody-drug conjugate that binds an undisclosed target, and the company’s Pointillist discovery platform. The round was co-led by RA Capital, a16z Bio+Health and Nextech Invest. Existing investors, including Emerson Collective Investments (managed by Yosemite), GV (Google Ventures), Lola Capital Partners, GordonMD Global Investments and others, also participated in the round.]]>
      </description>
      <guid>http://www.bioworld.com/articles/730206</guid>
      <pubDate>Tue, 07 Apr 2026 09:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/730206-stipple-launches-with-100m-for-novel-oncology-targets</link>
      <media:content url="https://www.bioworld.com/ext/resources/Stock-images/Money/Dollar-sign-in-light-bulb-on-yellow-background.webp?t=1637008317" type="image/png" medium="image" fileSize="77494">
        <media:title type="plain">Dollar sign in light bulb on yellow background</media:title>
      </media:content>
    </item>
    <item>
      <title>Stipple launches with $100M for novel oncology targets</title>
      <description>
        <![CDATA[Stipple Bio Inc. raised $100 million in a series A financing to support progression of the company’s lead drug, STP-100, an antibody-drug conjugate that binds an undisclosed target, and the company’s Pointillist discovery platform.]]>
      </description>
      <guid>http://www.bioworld.com/articles/730120</guid>
      <pubDate>Mon, 06 Apr 2026 12:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/730120-stipple-launches-with-100m-for-novel-oncology-targets</link>
      <media:content url="https://www.bioworld.com/ext/resources/Stock-images/Money/Dollar-sign-in-light-bulb-on-yellow-background.webp?t=1637008317" type="image/png" medium="image" fileSize="77494">
        <media:title type="plain">Dollar sign in light bulb on yellow background</media:title>
      </media:content>
    </item>
    <item>
      <title>Braveheart finds phase II positive for cardiac myosin inhibitor </title>
      <description>
        <![CDATA[Braveheart Bio Inc. reported positive results from an open-label randomized phase II dose-ranging study of BHB-1893 (HRS-1893) in obstructive hypertrophic cardiomyopathy. Results presented at the American College of Cardiology’s Annual Scientific Session and Expo in New Orleans showed BHB-1893 treatment was associated with rapid and substantial reductions in left ventricular outflow tract gradient, the primary endpoint of the study.]]>
      </description>
      <guid>http://www.bioworld.com/articles/729968</guid>
      <pubDate>Tue, 31 Mar 2026 12:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/729968-braveheart-finds-phase-ii-positive-for-cardiac-myosin-inhibitor</link>
      <media:content url="https://www.bioworld.com/ext/resources/Stock-images/Therapeutic-topics/Cardiovascular/heart-cross-section-valves.webp?t=1626905884" type="image/png" medium="image" fileSize="922624">
        <media:title type="plain">3D illustration of heart cross section</media:title>
      </media:content>
    </item>
    <item>
      <title>How to grow a startup in the AI era: MedTech Spotlight Korea 2026 </title>
      <description>
        <![CDATA[AI and advanced biotechnology are reshaping South Korea’s med-tech sector, but great technology alone is not enough to build a successful medical device company, speakers said at MedTech Innovator’s Medtech Spotlight: New Impact Korea 2026.]]>
      </description>
      <guid>http://www.bioworld.com/articles/729896</guid>
      <pubDate>Tue, 24 Mar 2026 12:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/729896-how-to-grow-a-startup-in-the-ai-era-medtech-spotlight-korea-2026</link>
      <media:content url="https://www.bioworld.com/ext/resources/Stock-images/Newco/AI-startup-art-concept.webp?t=1774299523" type="image/jpeg" medium="image" fileSize="387241">
        <media:title type="plain">AI startup art concept</media:title>
      </media:content>
    </item>
    <item>
      <title>Immutrin raises £65M series A to take another run at reversing amyloidosis</title>
      <description>
        <![CDATA[Newco Immutrin Ltd. has raised £65 million (US$86.9 million) in a series A to take its lead antibody program through to clinical proof of concept in transthyretin amyloid cardiomyopathy.]]>
      </description>
      <guid>http://www.bioworld.com/articles/729825</guid>
      <pubDate>Tue, 24 Mar 2026 12:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/729825-immutrin-raises-65m-series-a-to-take-another-run-at-reversing-amyloidosis</link>
      <media:content url="https://www.bioworld.com/ext/resources/Stock-images/Therapeutic-topics/Cardiovascular/Heart-scientific-overlay.webp?t=1729781889" type="image/jpeg" medium="image" fileSize="394419">
        <media:title type="plain">Heart scientific overlay</media:title>
      </media:content>
    </item>
    <item>
      <title>Financing at Immutrin to advance antibody for ATTR cardiomyopathy</title>
      <description>
        <![CDATA[Immutrin Ltd. has successfully raised £65 million ($87 million) in series A financing to advance its lead asset through clinical proof of concept in ATTR cardiomyopathy. Immutrin’s novel antibody selectively binds to amyloid fibrils and is engineered to deplete amyloid deposits in tissue via a targeted and coordinated immune response.]]>
      </description>
      <guid>http://www.bioworld.com/articles/729856</guid>
      <pubDate>Tue, 24 Mar 2026 09:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/729856-financing-at-immutrin-to-advance-antibody-for-attr-cardiomyopathy</link>
      <media:content url="https://www.bioworld.com/ext/resources/Stock-images/Therapeutic-topics/Cardiovascular/cardiology-heart-illustration.webp?t=1601070099" type="image/png" medium="image" fileSize="948393">
        <media:title type="plain">Colorful illustration of the heart</media:title>
      </media:content>
    </item>
    <item>
      <title>How to grow a startup in the AI era: MedTech Spotlight Korea 2026 </title>
      <description>
        <![CDATA[AI and advanced biotechnology are reshaping South Korea’s med-tech sector, but great technology alone is not enough to build a successful medical device company, speakers said at MedTech Innovator’s Medtech Spotlight: New Impact Korea 2026.]]>
      </description>
      <guid>http://www.bioworld.com/articles/729811</guid>
      <pubDate>Mon, 23 Mar 2026 12:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/729811-how-to-grow-a-startup-in-the-ai-era-medtech-spotlight-korea-2026</link>
      <media:content url="https://www.bioworld.com/ext/resources/Stock-images/Newco/AI-startup-art-concept.webp?t=1774299523" type="image/jpeg" medium="image" fileSize="387241">
        <media:title type="plain">AI startup art concept</media:title>
      </media:content>
    </item>
    <item>
      <title>Oryon emerges with autologous stem cell therapy for Parkinson’s</title>
      <description>
        <![CDATA[Oryon Cell Therapies, named after the Orion constellation used for navigation at night, emerged from stealth mode to announce a new round of funding and to present data from the phase Ib/IIa study of its neuron replacement therapy in patients with Parkinson’s disease at the 20th International Conference on Alzheimer’s and Parkinson’s Diseases.]]>
      </description>
      <guid>http://www.bioworld.com/articles/729809</guid>
      <pubDate>Mon, 23 Mar 2026 12:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/729809-oryon-emerges-with-autologous-stem-cell-therapy-for-parkinsons</link>
      <media:content url="https://www.bioworld.com/ext/resources/Stock-images/Therapeutic-topics/Neurology/Parkinson's-disease-illustration.webp?t=1643408215" type="image/png" medium="image" fileSize="519828">
        <media:title type="plain">Parkinson's disease illustration showing neurons containing alpha-synuclein</media:title>
      </media:content>
    </item>
    <item>
      <title>Series A financing at VST Bio to advance VB-001 into clinic</title>
      <description>
        <![CDATA[VST Bio Corp. has closed its series A financing designed to support the company’s work in vascular diseases with the development of first-in-class antibodies targeting edema and inflammation for patients with ischemic stroke.]]>
      </description>
      <guid>http://www.bioworld.com/articles/729690</guid>
      <pubDate>Wed, 18 Mar 2026 09:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/729690-series-a-financing-at-vst-bio-to-advance-vb-001-into-clinic</link>
      <media:content url="https://www.bioworld.com/ext/resources/Stock-images/Deals-and-MAs/Deal-illustration.webp?t=1755091469" type="image/png" medium="image" fileSize="522090">
        <media:title type="plain">Doctor with brain illustration, businessman with dollar sign illustration</media:title>
      </media:content>
    </item>
    <item>
      <title>R1’s $77.5M series A to fund CKD trial of oral phosphate inhibitor</title>
      <description>
        <![CDATA[Newco R1 Therapeutics Inc. has launched with an oversubscribed $77.5 million series A, providing the means to take AP-306, a potentially first-in-class hyperphosphatemia therapy through phase IIb development in patients with chronic kidney disease.]]>
      </description>
      <guid>http://www.bioworld.com/articles/729551</guid>
      <pubDate>Tue, 17 Mar 2026 08:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/729551-r1s-775m-series-a-to-fund-ckd-trial-of-oral-phosphate-inhibitor</link>
      <media:content url="https://www.bioworld.com/ext/resources/Stock-images/Therapeutic-topics/Nephrology/kidney-nephrology.webp?t=1589217921" type="image/png" medium="image" fileSize="520589">
        <media:title type="plain">Kidneys</media:title>
      </media:content>
    </item>
    <item>
      <title> ‘Dial is stuck’ on progress in female leadership in UK biotech   </title>
      <description>
        <![CDATA[One year on from establishing the baseline on female representation in the U.K. biotech industry, the latest survey shows the “dial is stuck.” Since the first report, representation at the CEO level has crept from 18.3% to 18.7%. That is “a marginal gain that signals a plateau at a time when we need a breakthrough,” said Jane Wall, managing director of the U.K. Bioindustry Association, which compiled the statistics.]]>
      </description>
      <guid>http://www.bioworld.com/articles/729358</guid>
      <pubDate>Fri, 06 Mar 2026 12:00:00 -0500</pubDate>
      <link>https://www.bioworld.com/articles/729358-dial-is-stuck-on-progress-in-female-leadership-in-uk-biotech</link>
      <media:content url="https://www.bioworld.com/ext/resources/BW-source/2026/Employees-in-a-meeting-room.webp?t=1772833318" type="image/jpeg" medium="image" fileSize="381483">
        <media:title type="plain">Employees in a meeting room </media:title>
      </media:content>
    </item>
    <item>
      <title>Antiverse announces series A financing, tie-up with CF Foundation</title>
      <description>
        <![CDATA[Antiverse Ltd. has announced the close of a $9.3 million series A financing. The funding will support expansion of the company’s proprietary AI antibody design platform, accelerate development of its internal therapeutic pipeline, and advance lead antibody programs toward in vivo efficacy studies.]]>
      </description>
      <guid>http://www.bioworld.com/articles/729324</guid>
      <pubDate>Wed, 04 Mar 2026 08:00:00 -0500</pubDate>
      <link>https://www.bioworld.com/articles/729324-antiverse-announces-series-a-financing-tie-up-with-cf-foundation</link>
      <media:content url="https://www.bioworld.com/ext/resources/BWS/BWS-library/Antibodies-research-discovery-immune.webp?t=1772641847" type="image/jpeg" medium="image" fileSize="240482">
        <media:title type="plain">Illustration of magnifying glass and antibodies</media:title>
      </media:content>
    </item>
    <item>
      <title>Slate Medicines launches with focus on headache disorders</title>
      <description>
        <![CDATA[Slate Medicines Inc. has launched with $130 million in series A financing and a focus on advancing next-generation therapeutics for migraine and other headache disorders.]]>
      </description>
      <guid>http://www.bioworld.com/articles/729036</guid>
      <pubDate>Wed, 25 Feb 2026 08:00:00 -0500</pubDate>
      <link>https://www.bioworld.com/articles/729036-slate-medicines-launches-with-focus-on-headache-disorders</link>
      <media:content url="https://www.bioworld.com/ext/resources/Stock-images/Therapeutic-topics/Neurology/Migraine-illustration.webp?t=1720189696" type="image/jpeg" medium="image" fileSize="134615">
        <media:title type="plain">Concept art for headache</media:title>
      </media:content>
    </item>
    <item>
      <title>New funding supports Centauri’s antimicrobial CTX-187</title>
      <description>
        <![CDATA[Centauri Therapeutics Ltd. has extended its series A financing round to £30 million (US$40.5 million) with the addition of a new £6 million (US$8 million) investment. Centauri initially closed its £24 million (US$32 million) series A round in 2022.]]>
      </description>
      <guid>http://www.bioworld.com/articles/729016</guid>
      <pubDate>Tue, 24 Feb 2026 08:00:00 -0500</pubDate>
      <link>https://www.bioworld.com/articles/729016-new-funding-supports-centauris-antimicrobial-ctx-187</link>
      <media:content url="https://www.bioworld.com/ext/resources/Stock-images/Therapeutic-topics/Infectious/Bacteria-magnifying-glass-research.webp?t=1771946941" type="image/jpeg" medium="image" fileSize="760577">
        <media:title type="plain">Art concept for antimicrobial research</media:title>
      </media:content>
    </item>
    <item>
      <title>Funding supports Third Arc Bio’s oncology and immunology programs</title>
      <description>
        <![CDATA[Third Arc Bio Inc. has closed a $52 million series A extension to advance its pipeline of multifunctional antibodies for a range of oncology and immunology & inflammation (I&I) indications.]]>
      </description>
      <guid>http://www.bioworld.com/articles/728629</guid>
      <pubDate>Thu, 05 Feb 2026 08:00:00 -0500</pubDate>
      <link>https://www.bioworld.com/articles/728629-funding-supports-third-arc-bios-oncology-and-immunology-programs</link>
      <media:content url="https://www.bioworld.com/ext/resources/Stock-images/Drugs/Monoclonal-antibody-therapy.webp?t=1731516507" type="image/jpeg" medium="image" fileSize="136228">
        <media:title type="plain">Illustration of monoclonal antibody hovering between doctor's hands</media:title>
      </media:content>
    </item>
    <item>
      <title>Series A financing at Ervimmune to advance ErVac-01</title>
      <description>
        <![CDATA[Ervimmune SAS has announced the first closing of its series A financing with €17 million ($19.8 million) raised to advance ErVac-01, Ervimmune’s lead candidate, into the clinic and through a first-in-human trial.]]>
      </description>
      <guid>http://www.bioworld.com/articles/728209</guid>
      <pubDate>Thu, 22 Jan 2026 08:00:00 -0500</pubDate>
      <link>https://www.bioworld.com/articles/728209-series-a-financing-at-ervimmune-to-advance-ervac-01</link>
      <media:content url="https://www.bioworld.com/ext/resources/BWS/BWS-library/cold-tumor-target.webp?t=1709311521" type="image/jpeg" medium="image" fileSize="245398">
        <media:title type="plain">Art concept for targeting a cold tumor</media:title>
      </media:content>
    </item>
    <item>
      <title>Rage Bio enters clinic with inhaled oligonucleotide in COPD</title>
      <description>
        <![CDATA[After raising AU$29 million (US$19.44 million) in a series A round, Rage Biotech Pty Ltd. is beginning phase I trials of its lead candidate, RB-042, an inhaled splice-switching oligonucleotide for treating chronic obstructive pulmonary disease (COPD) and other inflammatory lung diseases.]]>
      </description>
      <guid>http://www.bioworld.com/articles/728046</guid>
      <pubDate>Wed, 14 Jan 2026 09:00:00 -0500</pubDate>
      <link>https://www.bioworld.com/articles/728046-rage-bio-enters-clinic-with-inhaled-oligonucleotide-in-copd</link>
      <media:content url="https://www.bioworld.com/ext/resources/BWS/BWS-library/Respiratory-lungs-inflammation.webp?t=1698075497" type="image/jpeg" medium="image" fileSize="261810">
        <media:title type="plain">AI generated illustration of lungs in the human body</media:title>
      </media:content>
    </item>
    <item>
      <title>Rage Bio enters clinic with inhaled oligonucleotide in COPD</title>
      <description>
        <![CDATA[After raising AU$29 million (US$19.44 million) in a series A round, Rage Biotech Pty Ltd. is beginning phase I trials of its lead candidate, RB-042, an inhaled splice-switching oligonucleotide for treating chronic obstructive pulmonary disease (COPD) and other inflammatory lung diseases.]]>
      </description>
      <guid>http://www.bioworld.com/articles/727978</guid>
      <pubDate>Tue, 13 Jan 2026 00:00:00 -0500</pubDate>
      <link>https://www.bioworld.com/articles/727978-rage-bio-enters-clinic-with-inhaled-oligonucleotide-in-copd</link>
      <media:content url="https://www.bioworld.com/ext/resources/BWS/BWS-library/Respiratory-lungs-inflammation.webp?t=1698075497" type="image/jpeg" medium="image" fileSize="261810">
        <media:title type="plain">AI generated illustration of lungs in the human body</media:title>
      </media:content>
    </item>
    <item>
      <title>Rage Bio enters clinic with inhaled oligonucleotide in COPD</title>
      <description>
        <![CDATA[After raising AU$29 million (US$19.44 million) in a series A round, Rage Biotech Pty Ltd. is beginning phase I trials of its lead candidate, RB-042, an inhaled splice-switching oligonucleotide for treating chronic obstructive pulmonary disease (COPD) and other inflammatory lung diseases.]]>
      </description>
      <guid>http://www.bioworld.com/articles/727869</guid>
      <pubDate>Mon, 12 Jan 2026 12:00:00 -0500</pubDate>
      <link>https://www.bioworld.com/articles/727869-rage-bio-enters-clinic-with-inhaled-oligonucleotide-in-copd</link>
      <media:content url="https://www.bioworld.com/ext/resources/BWS/BWS-library/Respiratory-lungs-inflammation.webp?t=1698075497" type="image/jpeg" medium="image" fileSize="261810">
        <media:title type="plain">AI generated illustration of lungs in the human body</media:title>
      </media:content>
    </item>
    <item>
      <title>Psithera spun out of Roivant with $47.5M and immune, inflammatory focus</title>
      <description>
        <![CDATA[December 2025 was a big month for announcements from Psithera Inc. The Watertown, Mass.-based newco announced its name change from Psivant Therapeutics, having come out from under the Roivant Sciences Ltd. umbrella – thus the dropping of the “-vant” name. The company also announced a $47.5 million series A financing and disclosed that Eric Shaff had started as the company’s new president and CEO.]]>
      </description>
      <guid>http://www.bioworld.com/articles/727732</guid>
      <pubDate>Mon, 05 Jan 2026 09:00:00 -0500</pubDate>
      <link>https://www.bioworld.com/articles/727732-psithera-spun-out-of-roivant-with-475m-and-immune-inflammatory-focus</link>
      <media:content url="https://www.bioworld.com/ext/resources/BW-source/2026/Eric-Shaff-president-CEO-Psithera-1-2.webp?t=1767384744" type="image/jpeg" medium="image" fileSize="219453">
        <media:title type="plain">Eric Shaff, president and CEO, Psithera</media:title>
        <media:description type="plain">Eric Shaff, president and CEO, Psithera</media:description>
      </media:content>
    </item>
    <item>
      <title>Psithera spun out of Roivant with $47.5M and immune, inflammatory focus</title>
      <description>
        <![CDATA[December 2025 was a big month for announcements from Psithera Inc. The Watertown, Mass.-based newco announced its name change from Psivant Therapeutics, having come out from under the Roivant Sciences Ltd. umbrella – thus the dropping of the “-vant” name. The company also announced a $47.5 million series A financing and disclosed that Eric Shaff had started as the company’s new president and CEO.]]>
      </description>
      <guid>http://www.bioworld.com/articles/727543</guid>
      <pubDate>Fri, 02 Jan 2026 12:00:00 -0500</pubDate>
      <link>https://www.bioworld.com/articles/727543-psithera-spun-out-of-roivant-with-475m-and-immune-inflammatory-focus</link>
      <media:content url="https://www.bioworld.com/ext/resources/BW-source/2026/Eric-Shaff-president-CEO-Psithera-1-2.webp?t=1767384744" type="image/jpeg" medium="image" fileSize="219453">
        <media:title type="plain">Eric Shaff, president and CEO, Psithera</media:title>
        <media:description type="plain">Eric Shaff, president and CEO, Psithera</media:description>
      </media:content>
    </item>
    <item>
      <title>Bayosthiti AI to build India-specific RNA sequencing ecosystem</title>
      <description>
        <![CDATA[Bayosthiti AI Pvt Ltd. aims to make RNA sequencing and AI-based preventive health care affordable and accessible for the Indian market, leveraging intellectual property from its parent company, Biostate AI Inc.]]>
      </description>
      <guid>http://www.bioworld.com/articles/727660</guid>
      <pubDate>Wed, 31 Dec 2025 09:00:00 -0500</pubDate>
      <link>https://www.bioworld.com/articles/727660-bayosthiti-ai-to-build-india-specific-rna-sequencing-ecosystem</link>
      <media:content url="https://www.bioworld.com/ext/resources/BMT-source/2021/thumb/India-digital-map.webp?t=1632951244" type="image/png" medium="image" fileSize="470231">
        <media:title type="plain">India map on technology concept background</media:title>
      </media:content>
    </item>
    <item>
      <title>Bayosthiti AI to build India-specific RNA sequencing ecosystem</title>
      <description>
        <![CDATA[Bayosthiti AI Pvt Ltd. aims to make RNA sequencing and AI-based preventive health care affordable and accessible for the Indian market, leveraging intellectual property from its parent company, Biostate AI Inc.]]>
      </description>
      <guid>http://www.bioworld.com/articles/727213</guid>
      <pubDate>Tue, 23 Dec 2025 00:00:00 -0500</pubDate>
      <link>https://www.bioworld.com/articles/727213-bayosthiti-ai-to-build-india-specific-rna-sequencing-ecosystem</link>
      <media:content url="https://www.bioworld.com/ext/resources/BMT-source/2021/thumb/India-digital-map.webp?t=1632951244" type="image/png" medium="image" fileSize="470231">
        <media:title type="plain">India map on technology concept background</media:title>
      </media:content>
    </item>
    <item>
      <title>Syremis Therapeutics launches with focus on mental health</title>
      <description>
        <![CDATA[Syremis Therapeutics Ltd. has launched with $165 million in series A funding to develop novel medicines for the treatment of mental health disorders.]]>
      </description>
      <guid>http://www.bioworld.com/articles/727408</guid>
      <pubDate>Mon, 22 Dec 2025 08:00:00 -0500</pubDate>
      <link>https://www.bioworld.com/articles/727408-syremis-therapeutics-launches-with-focus-on-mental-health</link>
      <media:content url="https://www.bioworld.com/ext/resources/Stock-images/Therapeutic-topics/Neurology/Mental-illness-art-concept.webp?t=1750710518" type="image/jpeg" medium="image" fileSize="333024">
        <media:title type="plain">Mental illness art concept</media:title>
      </media:content>
    </item>
    <item>
      <title>Epilepsygtx's $33M advances focal epilepsy gene therapy </title>
      <description>
        <![CDATA[Epilepsygtx Ltd. has raised a $33 million series A to fund a phase I/IIa trial of EPY-201, a gene therapy for treating drug-resistant focal epilepsy. EPY-201 uses an adeno-associated viral vector to deliver KCNA1, the gene encoding Kv1.1, a potassium ion channel that modulates neuronal excitability.]]>
      </description>
      <guid>http://www.bioworld.com/articles/727125</guid>
      <pubDate>Thu, 11 Dec 2025 09:00:00 -0500</pubDate>
      <link>https://www.bioworld.com/articles/727125-epilepsygtxs-33m-advances-focal-epilepsy-gene-therapy</link>
      <media:content url="https://www.bioworld.com/ext/resources/Stock-images/Therapeutic-topics/Neurology/brain-neuro-dna.webp?t=1745264981" type="image/jpeg" medium="image" fileSize="555555">
        <media:title type="plain">Brain and DNA</media:title>
      </media:content>
    </item>
    <item>
      <title>Epilepsygtx's $33M advances focal epilepsy gene therapy </title>
      <description>
        <![CDATA[Epilepsygtx Ltd. has raised a $33 million series A to fund a phase I/IIa trial of EPY-201, a gene therapy for treating drug-resistant focal epilepsy.]]>
      </description>
      <guid>http://www.bioworld.com/articles/726891</guid>
      <pubDate>Wed, 10 Dec 2025 12:00:00 -0500</pubDate>
      <link>https://www.bioworld.com/articles/726891-epilepsygtxs-33m-advances-focal-epilepsy-gene-therapy</link>
      <media:content url="https://www.bioworld.com/ext/resources/Stock-images/Therapeutic-topics/Neurology/brain-neuro-dna.webp?t=1745264981" type="image/jpeg" medium="image" fileSize="555555">
        <media:title type="plain">Brain and DNA</media:title>
      </media:content>
    </item>
    <item>
      <title>Phrontline raises $60M in pre-A+ round for bispecific ADCs </title>
      <description>
        <![CDATA[Phrontline Biopharma Suzhou Co. Ltd. closed a $60 million pre-A+ financing round led by Lapam Investment, with participation from nine other investors. The funds raised will support Phrontline’s development of next-generation antibody-drug conjugate (ADC) candidates.]]>
      </description>
      <guid>http://www.bioworld.com/articles/726497</guid>
      <pubDate>Tue, 25 Nov 2025 12:00:00 -0500</pubDate>
      <link>https://www.bioworld.com/articles/726497-phrontline-raises-60m-in-pre-a-round-for-bispecific-adcs</link>
      <media:content url="https://www.bioworld.com/ext/resources/Stock-images/Research-and-science/Red-and-blue-bispecific-antibodies.webp?t=1765991281" type="image/jpeg" medium="image" fileSize="372546">
        <media:title type="plain">Red and blue bispecific antibodies</media:title>
      </media:content>
    </item>
  </channel>
</rss>
